Dong-A ST Co., Ltd. (170900.KS)
KRW 47300.0
(-1.77%)
KRW 47300.0
(-1.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 37.52 Billion KRW | -9.24% |
| 2022 | 49.39 Billion KRW | -0.09% |
| 2021 | 35.5 Billion KRW | -14.98% |
| 2020 | 58.84 Billion KRW | -59.93% |
| 2019 | 77.04 Billion KRW | 163.07% |
| 2018 | 59.47 Billion KRW | 89.03% |
| 2017 | 44.66 Billion KRW | -30.32% |
| 2016 | 33.65 Billion KRW | -62.54% |
| 2015 | 77.84 Billion KRW | 11.45% |
| 2014 | 74.28 Billion KRW | 76.9% |
| 2013 | 49.07 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.12 Billion KRW | -387.04% |
| 2024 Q2 | 1.15 Billion KRW | 112.61% |
| 2023 Q2 | 81.16 Billion KRW | 6.07% |
| 2023 Q3 | 79.74 Billion KRW | -1.75% |
| 2023 Q1 | 76.51 Billion KRW | 1920.68% |
| 2023 Q4 | 3.18 Billion KRW | -96.01% |
| 2023 FY | - KRW | -9.24% |
| 2022 Q4 | 3.78 Billion KRW | -80.91% |
| 2022 Q2 | 9.62 Billion KRW | -87.29% |
| 2022 Q1 | 75.71 Billion KRW | 3121.64% |
| 2022 FY | - KRW | -0.09% |
| 2022 Q3 | 19.83 Billion KRW | 106.04% |
| 2021 Q1 | 5.87 Billion KRW | 184.85% |
| 2021 Q3 | 16.55 Billion KRW | 28.52% |
| 2021 Q4 | 2.35 Billion KRW | -85.8% |
| 2021 FY | - KRW | -14.98% |
| 2021 Q2 | 12.88 Billion KRW | 119.29% |
| 2020 Q3 | 11.76 Billion KRW | 363.74% |
| 2020 FY | - KRW | -59.93% |
| 2020 Q2 | -4.46 Billion KRW | -107.68% |
| 2020 Q1 | 58.06 Billion KRW | 15.99% |
| 2020 Q4 | -6.92 Billion KRW | -158.84% |
| 2019 FY | - KRW | 163.07% |
| 2019 Q4 | 50.06 Billion KRW | 88.67% |
| 2019 Q3 | 26.53 Billion KRW | 77.27% |
| 2019 Q2 | 14.96 Billion KRW | -41.27% |
| 2019 Q1 | 25.48 Billion KRW | 233.68% |
| 2018 Q2 | 35.99 Billion KRW | 123.74% |
| 2018 FY | - KRW | 89.03% |
| 2018 Q3 | 13.15 Billion KRW | -63.44% |
| 2018 Q4 | -19.06 Billion KRW | -244.89% |
| 2018 Q1 | 16.08 Billion KRW | 368.65% |
| 2017 Q2 | 15.45 Billion KRW | 328.06% |
| 2017 Q1 | -6.77 Billion KRW | -142.31% |
| 2017 Q3 | 21.73 Billion KRW | 40.65% |
| 2017 FY | - KRW | -30.32% |
| 2017 Q4 | -5.98 Billion KRW | -127.55% |
| 2016 Q4 | 16.01 Billion KRW | 3611.66% |
| 2016 FY | - KRW | -62.54% |
| 2016 Q1 | 17.06 Billion KRW | 3.59% |
| 2016 Q2 | 3.88 Billion KRW | -77.24% |
| 2016 Q3 | -456.13 Million KRW | -111.74% |
| 2015 FY | - KRW | 11.45% |
| 2015 Q3 | 31.15 Billion KRW | 22.02% |
| 2015 Q2 | 25.53 Billion KRW | 25.02% |
| 2015 Q1 | 20.42 Billion KRW | -11.96% |
| 2015 Q4 | 16.47 Billion KRW | -47.13% |
| 2014 Q1 | 20.61 Billion KRW | -12.3% |
| 2014 Q2 | 18.59 Billion KRW | -9.84% |
| 2014 Q3 | 22.51 Billion KRW | 21.13% |
| 2014 Q4 | 23.2 Billion KRW | 3.03% |
| 2014 FY | - KRW | 76.9% |
| 2013 Q2 | 18.48 Billion KRW | 226.92% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q1 | -14.56 Billion KRW | 0.0% |
| 2013 Q3 | 20.04 Billion KRW | 8.44% |
| 2013 Q4 | 23.51 Billion KRW | 17.32% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -672.303% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 73.458% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -148.184% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 173.243% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 158.594% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -5.734% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 3719.717% |
| Yuhan Corporation | 127.43 Billion KRW | 70.556% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 273.007% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -651.877% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -996.795% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -728.939% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -2.42% |
| CKD Bio Corp. | -1.63 Billion KRW | 2401.281% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -672.303% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -472.407% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 176.12% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 57.946% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 201.225% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -184.044% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -390.483% |
| HANDOK Inc. | 35.06 Billion KRW | -6.999% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -672.303% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 31.746% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 77.248% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 57.946% |
| Yuhan Corporation | 127.43 Billion KRW | 70.556% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -12.084% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 88.396% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 86.771% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 51.289% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 57.946% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 39.758% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 303.126% |
| JW Holdings Corporation | 187.88 Billion KRW | 80.03% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -217.226% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -101.133% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 201.225% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 24.646% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 46.989% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -1.931% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -15.232% |
| Boryung Corporation | 114.28 Billion KRW | 67.17% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 222.745% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -148.184% |
| JW Lifescience Corporation | 50.82 Billion KRW | 26.182% |